| CYP17A1 inhibitor | |
|---|---|
| Drug class | |
 Abiraterone acetate, a steroidal CYP17A1 inhibitor that is used in the treatment of prostate cancer. | |
| Class identifiers | |
| Synonyms | Androgen synthesis inhibitors |
| Use | Prostate cancer, precocious puberty, breast cancer, others |
| ATC code | L02BX |
| Biological target | CYP17A1 |
| Chemical class | Steroidal; Nonsteroidal |
| Legal status | |
| In Wikidata | |
A CYP17A1 inhibitor is a type of drug which inhibits the enzyme CYP17A1.[1] It may inhibit both of the functions of the enzyme, 17α-hydroxylase and 17,20-lyase, or may be selective for inhibition of one of these two functions (generally 17,20-lyase).[2] These drugs prevent the conversion of pregnane steroids into androgens like testosterone and therefore are androgen biosynthesis inhibitors and functional antiandrogens. Examples of CYP17A1 inhibitors include the older drug ketoconazole and the newer drugs abiraterone acetate, orteronel, galeterone, and seviteronel.[3] The CYP17A1 inhibitors that have been marketed, like abiraterone acetate, are used mainly in the treatment of prostate cancer. CYP17A1 inhibitors that are not selective for inhibition of 17,20-lyase must be combined with a glucocorticoid such as prednisone in order to avoid adrenal insufficiency and mineralocorticoid excess caused by prevention of cortisol production.[4]
YouTube Encyclopedic
-
1/2Views:5946 083
-
Castration-Resistant Prostate Cancer: An Update
-
The Past, Present and Future of Congenital Adrenal Hyperplasia
Transcription
See also
- Steroidogenic enzyme
- Steroidogenesis inhibitor
- Nonsteroidal antiandrogen
- Gonadotropin-releasing hormone analogue
References
- ^ Malikova, Jana; Brixius-Anderko, Simone; Udhane, Sameer S.; Parween, Shaheena; Dick, Bernhard; Bernhardt, Rita; Pandey, Amit V. (2017-09-08). "CYP17A1 inhibitor abiraterone, an anti-prostate cancer drug, also inhibits the 21-hydroxylase activity of CYP21A2". The Journal of Steroid Biochemistry and Molecular Biology. 174: 192–200. doi:10.1016/j.jsbmb.2017.09.007. ISSN 1879-1220. PMID 28893623. S2CID 6270824.
- ^ Küçükemre-Aydın, Banu; Öğrendil-Yanar, Özlem; Bilge, Ilmay; Baş, Firdevs; Poyrazoğlu, Şükran; Yılmaz, Alev; Emre, Sevinç; Bundak, Rüveyde; Saka, Nurçin; Darendeliler, Feyza (2015). "An easily missed diagnosis: 17-alpha-hydroxylase/17,20-lyase deficiency". The Turkish Journal of Pediatrics. 57 (3): 277–281. ISSN 2791-6421. PMID 26701948.
- ^ Arth, G. E.; Patchett, A. A.; Jefopoulus, T.; Bugianesi, R. L.; Peterson, L. H.; Ham, E. A.; Kuehl, F. A.; Brink, N. G. (1971-08-01). "Steroidal androgen biosynthesis inhibitors". Journal of Medicinal Chemistry. 14 (8): 675–679. doi:10.1021/jm00290a003. ISSN 0022-2623. PMID 5114062.
- ^ Gomez, Lissette; Kovac, Jason R.; Lamb, Dolores J. (2014-12-22). "CYP17A1 inhibitors in castration-resistant prostate cancer". Steroids. 95: 80–87. doi:10.1016/j.steroids.2014.12.021. ISSN 1878-5867. PMC 4323677. PMID 25560485.
External links
Media related to CYP17A1 inhibitors at Wikimedia Commons
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
This page was last edited on 24 January 2024, at 13:33